Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG)

BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are standard of care for patients with EGFR mutation-positive non–small-cell lung cancer (NSCLC) with common mutations (Del19 or L858R); however, 7%-23% of NSCLC tumors harbor uncommon EGFR mutations. These mutations...

Descripción completa

Detalles Bibliográficos
Autores principales: Popat, Sanjay, Hsia, Te-Chun, Hung, Jen-Yu, Jung, Hyun Ae, Shih, Jin-Yuan, Park, Cheol Kyu, Lee, Seung Hyeun, Okamoto, Tatsuro, Ahn, Hee Kyung, Lee, Yong Chul, Sato, Yuki, Lee, Sung Sook, Mascaux, Celine, Daoud, Hasan, Märten, Angela, Miura, Satoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Academia-Pharma Intersect
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982383/
https://www.ncbi.nlm.nih.gov/pubmed/35274704
http://dx.doi.org/10.1093/oncolo/oyac022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982383/
https://www.ncbi.nlm.nih.gov/pubmed/35274704
http://dx.doi.org/10.1093/oncolo/oyac022

Ejemplares similares